双时间点治疗后177Lu-PSMA-617 SPECT/CT描述mCRPC病灶摄取动力学并预测患者结局
该回顾性研究纳入55例接受177Lu-PSMA-617治疗的mCRPC患者,分析首次治疗后24和48小时SPECT/CT上淋巴结转移灶和骨转移灶的注射剂量百分比下降率(%IDred)。结果显示无应答者%IDred高于应答者,且%IDred较大与更短的无进展生存和总生存相关,提示177Lu-PSMA-617从转移灶清除速率可能是反应和生存的相关预后因素。
要点
- 无应答者淋巴结转移灶%IDred为36%(IQR 26%-47%),高于应答者的24%(IQR 12%-33%)(P=0.003)。
- 无应答者骨转移灶%IDred为35%(IQR 27%-52%),高于应答者的18%(IQR 15%-29%)(P=0.002)。
- 多因素分析中,淋巴结转移灶%IDred与无进展生存独立相关(P=0.03),骨转移灶%IDred与总生存独立相关(P=0.009)。
核心结论
- 177Lu-PSMA-617从mCRPC转移灶的清除速率似乎是反应和生存的相关预后因素,清除较快可能提示放射性药物驻留时间和吸收剂量较短。
- 双时间点分析似乎是估计反应可能性和患者生存的可行且易得的方法。
研究设计与样本
- 回顾性纳入接受177Lu-PSMA-617治疗且具有首次治疗后24和48小时SPECT/CT图像的mCRPC患者。
- 在两次SPECT/CT上勾画淋巴结转移灶和骨转移灶的感兴趣区,计算两次扫描间的注射剂量百分比下降率(%IDred)。
- 比较应答者(2周期177Lu-PSMA-617后前列腺特异性抗原下降≥50%)与无应答者的%IDred。
- 采用单因素Kaplan-Meier分析和多因素Cox回归模型检验%IDred与无进展生存和总生存的关联。
主要发现
- 共纳入55例患者,中位年龄73岁(范围54-87岁)。
- 淋巴结转移灶%IDred无应答者为36%(IQR 26%-47%),高于应答者的24%(IQR 12%-33%)(P=0.003)。
- 骨转移灶%IDred无应答者为35%(IQR 27%-52%),高于应答者的18%(IQR 15%-29%)(P=0.002)。
- 无进展生存的单因素Kaplan-Meier分析中,淋巴结转移灶%IDred较大(P=0.008)和骨转移灶%IDred较大(P=0.001)与更短生存相关,多因素分析仅保留淋巴结转移灶%IDred(P=0.03)。
- 总生存的单因素Kaplan-Meier分析中,骨转移灶%IDred较大与更短生存相关(P=0.002),多因素分析保留骨转移灶%IDred(P=0.009)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant prostate cancer (mCRPC). However, some patients progress under treatment. We hypothesized that the tracer kinetics within the metastases may influence the therapy effectiveness and tested this hypothesis by analyzing uptake parameters on 2 consecutive posttherapy SPECT/CT scans. Methods: mCRPC patients treated with 177Lu-PSMA-617 and with available posttherapy SPECT/CT imaging (24 and 48 h after the first treatment) were enrolled retrospectively. Volumes of interest were defined on lymph node metastasis (LNM) and bone metastasis (BM) on both SPECT/CT scans. The reduction of the percentage injected dose (%IDred) between the 2 SPECT/CT scans was computed. We compared %IDred of responders (prostate-specific antigen drop ≥ 50% after 2 cycles of 177Lu-PSMA-617) and nonresponders. We tested the association of %IDred with progression-free survival and overall survival (OS) using a univariate Kaplan-Meier (KM) analysis and a multivariate Cox regression model. Results: Fifty-five patients (median age, 73 y; range, 54-87 y) were included. %IDred in LNM and BM was greater in nonresponders than in responders (for LNM, 36% in nonresponders [interquartile range (IQR), 26%-47%] vs. 24% in responders [IQR, 12%-33%] [P = 0.003]; for BM, 35% in nonresponders [IQR, 27%-52%] vs. 18% in responders [IQR, 15%-29%] [P = 0.002]). For progression-free survival, in KM analysis, greater %IDred in LNM (P = 0.008) and BM (P = 0.001) was associated with shorter survival, whereas in multivariate analysis, only %IDred in LNM was retained (P = 0.03). In univariate KM analysis of OS, greater %IDred in BM was associated with shorter survival (P = 0.002). In multivariate OS analysis, BM %IDred (P = 0.009) was retained. Conclusion: The 177Lu-PSMA-617 clearance rate from mCRPC metastases appears to be a relevant prognosticator of response and survival, with faster clearing possibly signaling a shorter radiopharmaceutical residence time and absorbed dose. Dual-time-point analysis appears to be a feasible and readily available approach to estimate the likelihood of response and patients' survival.
引用
- Straub M, Kupferschläger J, Serna Higuita LM, et al. Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome. J Nucl Med. 2023. PMID: 37414446. doi:10.2967/jnumed.122.264770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。